Nefrocarnit (Levocarnitine)

Levocarnitine transports long‑chain fatty acids into mitochondria by forming acyl‑carnitine complexes. Inside the mitochondrial matrix, these complexes are broken down through β‑oxidation, producing acetyl‑CoA for the citric acid cycle, thereby generating ATP and preventing the buildup of toxic fatty‑acid intermediates.

The appropriate dose of Nefrocarnit is determined by the prescribing clinician based on the patient’s age, weight, renal function, and specific clinical indication. Dosage regimens are individualized and should follow the prescribing information or institutional protocol.

Safety data for levocarnitine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Nefrocarnit is an intravenous formulation of levocarnitine, offering rapid systemic availability compared with oral carnitine salts, which may have variable absorption. IV delivery is preferred in acute settings, dialysis patients, or when oral intake is not feasible, providing more predictable plasma concentrations.

Nefrocarnit should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, inspect the solution for particulate matter or discoloration and use aseptic technique to maintain sterility.

Nefrocarnit is given by intravenous infusion. The infusion rate and duration are set by the prescribing clinician, typically over 30 minutes to several hours, depending on the indication and patient tolerance. Administration should be performed by trained healthcare personnel.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, seizures, cardiac arrhythmias, metabolic acidosis, and hyperkalemia. Patients should be monitored closely during and after infusion for any signs of these adverse events, and emergency measures should be readily available.

Nefrocarnit is contraindicated in individuals with known hypersensitivity to levocarnitine or any component of the formulation. Caution is advised for patients with a history of seizures, severe renal impairment, or those receiving medications that significantly interact with carnitine metabolism.